| Thursday, November 5, 2020
| |
|
CF Foundation Awards Up to $2.4M for a New Approach to Reduce Infections
The Foundation granted Calithera Biosciences Inc. up to $2.4 million to advance a potential treatment to reduce infections in the lungs of people with cystic fibrosis. Individuals with CF who have chronic infections are at a greater risk for worsening, life-threatening lung disease, making infections a top concern of both patients and clinicians.
| |
Get Covered During Open EnrollmentWhether you’re seeking insurance for the first time, you’ve lost your job due to COVID-19, or you want to explore a new plan that better meets your needs, Compass is here to help. Our dedicated team of case managers will work with you one-on-one to help answer your questions and ensure your plan provides the best possible coverage. Contact the Compass team now to get started.
| |
U.S. FDA Approves Bronchitol Inhalation PowderThe U.S. FDA approved Bronchitol (mannitol), an inhaled mucus clearance drug, for people with cystic fibrosis ages 18 years and older. The drug attracts water into the airways, hydrating mucus and making it easier to clear from the lungs.
| |
Register for our Sexual and Reproductive Health Webinar
Join us for a CF research webinar on Thursday, November 12 at 6 p.m. EST to learn about current and upcoming research to address the sexual and reproductive health needs of people with cystic fibrosis, including studies on pregnancy, parenthood, and care delivery. Plus, hear from members of the Therapeutics Development Network Women’s Health Research Working Group and have an opportunity to ask your research-related questions during an audience Q&A.
| |
|
|
|
|
